Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 8/20 | 0.52 |
| ▸ | POLR1A | O95602 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3398163 | 0.94 | HTR2C (0.57) | HTR2CCNR1POLBCES2OXTR | |
| SCHEMBL3399761 | 0.91 | HTR2C (0.53) | HTR2CPOLR1ACNR1JAK1CES2 | |
| SCHEMBL3405516 | 0.91 | HTR2C (0.53) | HTR2CCNR1JAK1POLBCES2 | |
| SCHEMBL3402535 | 0.89 | HTR2C (0.52) | HTR2CPOLR1ACNR1JAK1POLB | |
| SCHEMBL3405032 | 0.89 | HTR2C (0.69) | HTR2CPOLR1ACES2 | |
| SCHEMBL3404419 | 0.89 | HTR2C (0.51) | HTR2CPOLR1ACNR1JAK1CES2 | |
| SCHEMBL3405397 | 0.88 | HTR2C (0.50) | HTR2CPOLR1ACNR1JAK1CES2 | |
| SCHEMBL3402532 | 0.87 | HTR2C (0.52) | HTR2CPOLR1ACNR1JAK1CES2 | |
| SCHEMBL3405482 | 0.87 | HTR2C (0.52) | HTR2CPOLR1ACNR1JAK1CES2 | |
| SCHEMBL3405532 | 0.87 | HTR2C (0.56) | HTR2CPOLR1ACNR1JAK1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | LIGAND PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728009-B1 | Thiazole amides, imidazole amides and related analogues | NEUROGEN CORPORATION (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006089076-A9 | THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES | NEUROGEN CORP (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297035-A1 | Thiazole Amides, Imidazole Amides and Related Analogues | HRH3, HRH4, HRH2 | HTR2C 416/4885POLR1A 4685/4885CNR1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.